CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ (432,412,571)	$ 155,051,299
Adjustment to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	9,859,513	5,873,439
Impairment of goodwill	408,466,575	0
Stock-based compensation expense	135,415	0
Other income - gain on PPP loan forgiveness	0	(5,200,835)
Deferred tax expense	3,375,106	0
Debt accretion expense	1,719,572	0
Non-cash lease expense	18,775	(72,193)
Changes in operating assets and liabilities:
Accounts receivable	52,921,095	(35,601,637)
Accounts receivable - related party	1,846,887	(150)
Inventories	(399,198)	(4,880)
Prepaid expenses and other current assets	(5,629,042)	(415,003)
Accounts payable	4,147,170	6,040,929
Accounts payable - related party	(630,490)	(299,489)
Accrued expenses and other current liabilities	2,712,011	1,673,501
Other current assets	(29,704)	(36,643)
Net cash from operating activities	46,101,114	127,008,338
Cash flows from investing activities:
Acquisitions of property and equipment	(22,512,464)	(25,206,117)
Acquired cash in reverse acquisition with Clinigence	12,716,228	0
Cash related to deconsolidation of Real Estates Entities	(2,421,212)	0
Net cash from investing activities	(12,217,448)	(25,206,117)
Cash flows from financing activities:
Proceeds from lines of credit	2,592,714	320,430
Proceeds from notes payable	10,126,130	14,970,896
Repayments of lines of credit	(72,055)	(863,196)
Repayments of notes payable	(4,720,737)	(17,488,009)
Repayments of finance leases	(923,321)	(856,422)
Common stock issued for exercise of warrants	4,119,141	0
Common stock issued for exercise of options	644,974	0
Members' contributions	4,825,377	12,521,879
Members' distributions	(49,973,374)	(101,683,740)
Net cash from financing activities	(33,381,151)	(93,078,162)
Net change in cash and cash equivalents	502,515	8,724,059
Cash and cash equivalents - beginning of the period	36,118,284	25,514,275
Cash and cash equivalents - end of the period	$ 36,620,799	$ 34,238,334